Veru (VERU) Downgraded to Hold at Zacks Investment Research

Zacks Investment Research lowered shares of Veru (NASDAQ:VERU) from a buy rating to a hold rating in a report released on Wednesday morning, Zacks.com reports.

According to Zacks, “Veru Inc. engages in the development, manufacture and marketing of consumer health care products. It focuses on producing FC2 female condom which provides dual protection against unintended pregnancy and sexually transmitted infections. Veru Inc., formerly known as The Female Health Company, is headquartered in Miami, FL. “

Other equities research analysts have also issued research reports about the stock. Maxim Group set a $6.00 price objective on shares of Veru and gave the company a buy rating in a research note on Thursday, February 14th. CIBC began coverage on shares of Veru in a research note on Wednesday, March 20th. They issued an outperform rating and a $5.00 price objective for the company. Oppenheimer began coverage on shares of Veru in a research note on Tuesday, March 19th. They issued an outperform rating and a $5.00 price objective for the company. Finally, HC Wainwright reiterated a buy rating and issued a $4.50 price objective on shares of Veru in a research note on Wednesday, January 23rd. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The stock presently has a consensus rating of Buy and a consensus target price of $4.40.

NASDAQ:VERU opened at $1.41 on Wednesday. The company has a quick ratio of 1.30, a current ratio of 1.58 and a debt-to-equity ratio of 0.08. The stock has a market capitalization of $88.46 million, a price-to-earnings ratio of -3.62 and a beta of 0.91. Veru has a 52 week low of $1.18 and a 52 week high of $2.37.

Veru (NASDAQ:VERU) last posted its quarterly earnings data on Wednesday, February 13th. The company reported ($0.03) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.04) by $0.01. The firm had revenue of $6.37 million during the quarter, compared to analyst estimates of $9.71 million. Veru had a negative net margin of 111.10% and a negative return on equity of 60.83%. Equities analysts forecast that Veru will post -0.19 earnings per share for the current year.

In other news, insider Mitchell Shuster Steiner sold 49,899 shares of the firm’s stock in a transaction that occurred on Wednesday, March 20th. The shares were sold at an average price of $1.53, for a total transaction of $76,345.47. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In the last 90 days, insiders have bought 38,681 shares of company stock valued at $53,206 and have sold 125,600 shares valued at $184,632. Company insiders own 29.50% of the company’s stock.

Institutional investors have recently added to or reduced their stakes in the stock. Virtu Financial LLC purchased a new position in Veru in the 1st quarter valued at approximately $95,000. Dimensional Fund Advisors LP grew its stake in Veru by 328.8% in the 3rd quarter. Dimensional Fund Advisors LP now owns 102,909 shares of the company’s stock valued at $146,000 after buying an additional 78,909 shares in the last quarter. BlackRock Inc. grew its stake in Veru by 9.3% in the 4th quarter. BlackRock Inc. now owns 128,766 shares of the company’s stock valued at $180,000 after buying an additional 10,956 shares in the last quarter. Geode Capital Management LLC grew its stake in Veru by 115.4% in the 4th quarter. Geode Capital Management LLC now owns 215,601 shares of the company’s stock valued at $301,000 after buying an additional 115,506 shares in the last quarter. Finally, Vanguard Group Inc grew its stake in Veru by 1.2% in the 3rd quarter. Vanguard Group Inc now owns 1,199,963 shares of the company’s stock valued at $1,704,000 after buying an additional 13,650 shares in the last quarter. Institutional investors and hedge funds own 8.64% of the company’s stock.

Veru Company Profile

Veru Inc operates as an oncology and urology biopharmaceutical company. The company operates through two segments, Commercial, and Research and Development. It offers FC2 Female Condom for unintended pregnancy and sexually transmitted infections, including HIV/AIDS and the Zika virus; and PREBOOST benzocaine medicated individual wipes for the prevention of premature ejaculation.

Recommended Story: What type of investment options does a Roth IRA provide?

Get a free copy of the Zacks research report on Veru (VERU)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Veru (NASDAQ:VERU)

Receive News & Ratings for Veru Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veru and related companies with MarketBeat.com's FREE daily email newsletter.